The Pravetoni Lab

Phase 1a/1b Clinical Trials of Multicomponent Opioid Vaccines

National Institute on Drug Abuse

The long-term goal of this project is to develop a multivalent vaccine directed against oxycodone, heroin, and other relevant opioids.The studies outlined will provide a great deal of information about the safety and potential efficacy of the vaccines in reducing the abuse liability of opioids.

Antibody-based countermeasures to opioid toxicity and overdose

National Institute on Drug Abuse

The aim of this project is to enable the submission of IND applications for Oxy(Gly)4-dKLH, a vaccine directed against oxycodone and related prescription opioids, and M(Gly)4-dKLH, a vaccine directed against heroin and morphine. Long term, we aim for an IND submission for the co-administration of these two vaccines to treat abuse or addiction from a broad range of prescription or illicit opioids.

Enhancing efficacy of vaccines for substance abuse through polymer-assisted delivery of immunomodulators

National Institute on Drug Abuse

This project aims to develop an immunotherapeutic intervention for prescription opioid abuse that combines a lead oxycodone vaccine with immunomodulators formulated through a novel thermosensitive gelling polymer technology to enhance the post-vaccination antibody (Ab) response. Vaccines for substance use disorders (SUD) have the potential to be a long-lasting, safe, cheap, and effective intervention

Vaccines for fentanyl and its derivatives: a strategy against illicit use and overdoses

National Institute on Drug Abuse

This project aims to develop vaccines against fentanyl and fentanyl-like compounds as a strategy to reduce illicit opioid use and the incidence of fatal overdoses. Proposed activities will include lead vaccine selection and optimization, manufacturing of GMP vaccines, and IND-enabling GLP toxicology studies.